All studies
Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Seagen Inc.
Enrolment target
22
Start
10 Oct 2023
What is this study about?
CR rate at EOT
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (4)
- —Spain
- —Czechia
- —Italy
- —Poland
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.